Loo, Nicole

Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial

Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 379

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 217

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis

Siddiqui, M. S., Idowu, M. O., Parmar, D., Borg, B. B., Denham, D., Loo, N. M., Lazas, D., Younes, Z., & Sanyal, A. J. (2021) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 96